AstraZeneca's Lynparza Delivers Progression-Free Survival of Over 4 Years in Advanced Ovarian Cancer
AstraZeneca (NYSE: AZN) and Merck's (NYSE: MRK) drug Lynparza was approved for use as maintenance therapy in BRCA-positive, advanced ovarian cancer patients in 2018; on Friday, the healthcare companies unveiled long-term trial data that could increase its use in those patients.
Specifically, five-year follow-up data from a trial evaluating Lynparza in patients with mutations to their BRCA gene who also responded to platinum-based therapy showed that the drug reduces the risk of disease progression by 67% compared to placebo.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
